EP 1030671 A1 20000830 - COMBINATION OF SR 57746 AND ACETYLCHOLINESTERASE INHIBITING AGENTS FOR TREATING SENILE ALZHEIMER DEMENTIA
Title (en)
COMBINATION OF SR 57746 AND ACETYLCHOLINESTERASE INHIBITING AGENTS FOR TREATING SENILE ALZHEIMER DEMENTIA
Title (de)
WIRKSTOFFKOMBINATION AUS SR 57746 UND ACETYLCHOLINESTERASE-HEMMERN FÜR DIE BEHANDLUNG VON SENILER DEMENZ DES ALZHEIMERTYPES
Title (fr)
ASSOCIATION DU SR 57746 ET D'AGENTS INHIBITEURS DE L'ACETYLCHOLINESTERASE POUR LE TRAITEMENT DE LA DEMENCE SENILE DU TYPE ALZHEIMER
Publication
Application
Priority
- FR 9802384 W 19981109
- FR 9714322 A 19971114
- FR 9714324 A 19971114
Abstract (en)
[origin: WO9925363A1] The invention concerns a pharmaceutical composition containing as active principles: a constituent (a) selected between 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin and a compound (I) in which: Y represents -CH- or -N-; R1 represents hydrogen, a halogen, a hydroxyl, a CF3, a (C3-C4)alkyl or (C1-C4) alkoxyl group; R2 represents hydrogen, a halogen, a hydroxyl, a CF3, (C3-C4) alkyl or( C1-C4)alkoxyl group; R3 and R4 represent each hydrogen or a (C1-C4)alkyl; X represents (a) a (C3-C6)alkyl; a (C3-C6)alkoxyl; a (C3-C7)carboxyalkyl; a (C1-C4)alkoxycarbonyl(C3-C6-)alkyl; a (C3-C7)carboxyalkoxyl; or a (C1-C4)alkoxycarbonyl(C3-C6)alkoxyl; (b) a radical selected among a (C3-C7)cycloalkyl, (C3-C7)cycloalkyloxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, said radical capable of being substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino, mono- or di-(C1-C4)alkyamino or (c) a group selected among phenyl, phenoxy, phenylamino, N-(C1-C3)alkyl-phenyl-amino, phenylmethyl, phenylethyl, p henylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl and styryl, said group capable of being mono- or polysubstituted on the phenyl group by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alk yl, hydroxy(C1-C4)alkyl, or halogeno(C1-C4)alkyl; optionally in the form of one of its pharmaceutically acceptable salts; and an constituent (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts, provided that when constituent (a) is other than 1-(2napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin or one of its pharmaceutically acceptable salts, the constituent (b) is an acetylcholinesterase inhibiting agent.
IPC 1-7
IPC 8 full level
A61K 31/00 (2006.01); A61K 31/4409 (2006.01); A61K 31/4418 (2006.01); A61K 31/445 (2006.01); A61K 45/00 (2006.01); A61K 31/473 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01)
CPC (source: EP KR)
A61K 31/00 (2013.01 - EP); A61K 31/445 (2013.01 - EP); A61K 31/64 (2013.01 - KR); A61P 25/00 (2018.01 - EP); A61P 25/28 (2018.01 - EP)
C-Set (source: EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated extension state (EPC)
AL LT LV MK RO SI
DOCDB simple family (publication)
WO 9925363 A1 19990527; AU 1160999 A 19990607; AU 743228 B2 20020124; BG 104428 A 20010831; BG 64819 B1 20060531; BR 9814035 A 20000926; CA 2309966 A1 19990527; CN 1243540 C 20060301; CN 1285742 A 20010228; CO 4980891 A1 20001127; DZ 2649 A1 20041228; EA 003255 B1 20030227; EA 200000412 A1 20001225; EE 04235 B1 20040216; EE 200000290 A 20010615; EP 1030671 A1 20000830; HU P0100098 A2 20010730; HU P0100098 A3 20011228; ID 24933 A 20000831; IL 136122 A0 20010520; IL 136122 A 20060705; IS 5482 A 20000509; JP 2001523642 A 20011127; KR 100599350 B1 20060712; KR 20010032099 A 20010416; MY 120461 A 20051031; NO 20002450 D0 20000511; NO 20002450 L 20000714; NZ 504420 A 20030829; OA 11464 A 20031118; PL 194597 B1 20070629; PL 340500 A1 20010212; SA 98190747 B1 20061104; SK 286040 B6 20080107; SK 7112000 A3 20001009; TR 200001262 T2 20010122; TW 585766 B 20040501; UY 25247 A1 20010531
DOCDB simple family (application)
FR 9802384 W 19981109; AU 1160999 A 19981109; BG 10442800 A 20000511; BR 9814035 A 19981109; CA 2309966 A 19981109; CN 98813094 A 19981109; CO 98062479 A 19981026; DZ 980259 A 19981111; EA 200000412 A 19981109; EE P200000290 A 19981109; EP 98954538 A 19981109; HU P0100098 A 19981109; ID 20000860 A 19981109; IL 13612200 A 20000514; IL 13612298 A 19981109; IS 5482 A 20000509; JP 2000520796 A 19981109; KR 20007005231 A 20000513; MY PI9805180 A 19981114; NO 20002450 A 20000511; NZ 50442098 A 19981109; OA 1200000141 A 20000512; PL 34050098 A 19981109; SA 98190747 A 19981114; SK 7112000 A 19981109; TR 200001262 T 19981109; TW 87117874 A 19981028; UY 25247 A 19981112